Literature DB >> 33309859

IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway.

Longhao Sun1, Xuebin Zhang2, Qianqian Song3, Liang Liu3, Elizabeth Forbes3, Weijun Tian4, Zhixiang Zhang4, Ya'an Kang5, Huamin Wang6, Jason B Fleming7, Boris C Pasche3, Wei Zhang8.   

Abstract

Tumor-associated macrophages (TAMs) represent the M2-like phenotype with potent immunosuppressive activity, and play a pro-tumor role in pancreatic ductal adenocarcinoma (PDAC) biology. In this study, we investigated the role of the insulin-like growth factor binding protein 2 (IGFBP2) as a determinant of TAM polarity. Clinical data revealed that the levels of IGFBP2 correlated with M2 TAMs accumulation and disease progression in human PDAC. In vivo mouse model experiments showed that IGFBP2 promoted an immunosuppressive microenvironment and tumor growth in a macrophage dependent manner. Bioinformatics analysis of PDAC transcriptomes revealed a significant association between IGFBP2 expression and M2 macrophage polarization and signal transducer and activator of transcription 3 (STAT3) activation. Mechanistic investigations demonstrated that IGFBP2 augmented the expression and secretion of IL-10 through STAT3 activation in PDAC cells, which induced TAM polarization toward an M2 phenotype. IGFBP2-polarized M2 macrophages significantly increased Tregs infiltration and impaired antitumor T-cell immunity in a mouse model. Thus, our investigations have illuminated the IGFBP2 signaling pathway that contributes to the macrophage-based immunosuppressive microenvironment in PDAC, suggesting that blocking the IGFBP2 axis constitutes a potential treatment strategy to reset TAM polarization toward an antitumor state in PDAC.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  IGFBP2; PDAC; STAT3; TAM; alternative polarization

Mesh:

Substances:

Year:  2020        PMID: 33309859      PMCID: PMC7923838          DOI: 10.1016/j.canlet.2020.12.008

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  52 in total

1.  Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer.

Authors:  Takayuki Toyonaga; Kenji Nakano; Masahiro Nagano; Gang Zhao; Koji Yamaguchi; Syoji Kuroki; Takashi Eguchi; Kazuo Chijiiwa; Masazumi Tsuneyoshi; Masao Tanaka
Journal:  Cancer Lett       Date:  2003-11-10       Impact factor: 8.679

Review 2.  Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.

Authors:  John Condeelis; Jeffrey W Pollard
Journal:  Cell       Date:  2006-01-27       Impact factor: 41.582

3.  Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer.

Authors:  Ru Chen; Teresa A Brentnall; Sheng Pan; Kelly Cooke; Kara White Moyes; Zhaoli Lane; David A Crispin; David R Goodlett; Ruedi Aebersold; Mary P Bronner
Journal:  Mol Cell Proteomics       Date:  2007-05-12       Impact factor: 5.911

4.  Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy.

Authors:  Giuseppe Di Caro; Nina Cortese; Giovanni Francesco Castino; Fabio Grizzi; Francesca Gavazzi; Cristina Ridolfi; Giovanni Capretti; Rossana Mineri; Jelena Todoric; Alessandro Zerbi; Paola Allavena; Alberto Mantovani; Federica Marchesi
Journal:  Gut       Date:  2015-07-08       Impact factor: 23.059

5.  Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.

Authors:  Timothy M Nywening; Andrea Wang-Gillam; Dominic E Sanford; Brian A Belt; Roheena Z Panni; Brian M Cusworth; Adetunji T Toriola; Rebecca K Nieman; Lori A Worley; Motoyo Yano; Kathryn J Fowler; A Craig Lockhart; Rama Suresh; Benjamin R Tan; Kian-Huat Lim; Ryan C Fields; Steven M Strasberg; William G Hawkins; David G DeNardo; S Peter Goedegebuure; David C Linehan
Journal:  Lancet Oncol       Date:  2016-04-04       Impact factor: 41.316

6.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Vanja Vaccaro; Isabella Sperduti; Michele Milella
Journal:  N Engl J Med       Date:  2011-08-25       Impact factor: 91.245

7.  IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.

Authors:  Emmanuel Zorn; Erik A Nelson; Mehrdad Mohseni; Fabrice Porcheray; Haesook Kim; Despina Litsa; Roberto Bellucci; Elke Raderschall; Christine Canning; Robert J Soiffer; David A Frank; Jerome Ritz
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

8.  Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.

Authors:  R Mehrian-Shai; C D Chen; T Shi; S Horvath; S F Nelson; J K V Reichardt; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

9.  MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma.

Authors:  Swadesh K Das; Sujit K Bhutia; Belal Azab; Timothy P Kegelman; Leyla Peachy; Prasanna K Santhekadur; Santanu Dasgupta; Rupesh Dash; Paul Dent; Steven Grant; Luni Emdad; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Cancer Res       Date:  2012-12-10       Impact factor: 12.701

Review 10.  The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science.

Authors:  Daniel Ansari; Linus Aronsson; Agata Sasor; Charlotte Welinder; Melinda Rezeli; György Marko-Varga; Roland Andersson
Journal:  J Transl Med       Date:  2014-04-05       Impact factor: 5.531

View more
  7 in total

1.  The molecular feature of macrophages in tumor immune microenvironment of glioma patients.

Authors:  Hao Zhang; Yue-Bei Luo; Wantao Wu; Liyang Zhang; Zeyu Wang; Ziyu Dai; Songshan Feng; Hui Cao; Quan Cheng; Zhixiong Liu
Journal:  Comput Struct Biotechnol J       Date:  2021-08-14       Impact factor: 7.271

2.  An Aging and Senescence-Related Gene Signature for Prognosis Prediction in Clear Cell Renal Cell Carcinoma.

Authors:  Jiaying Li; Chengpeng Gui; Haohua Yao; Chenggong Luo; Hongde Song; Haishan Lin; Quanhui Xu; Xu Chen; Yong Huang; Junhang Luo; Wei Chen
Journal:  Front Genet       Date:  2022-05-13       Impact factor: 4.772

3.  A Novel 16-Genes Signature Scoring System as Prognostic Model to Evaluate Survival Risk in Patients with Glioblastoma.

Authors:  Zunpeng Yu; Manqing Du; Long Lu
Journal:  Biomedicines       Date:  2022-01-29

4.  Comprehensive Analysis on Prognosis and Immune Infiltration of Lysyl Oxidase Family Members in Pancreatic Adenocarcinoma With Experimental Verification.

Authors:  Chao Jiang; Meng Wang; Weikai Yao; Guoyue Lv; Xueyan Liu; Guangyi Wang
Journal:  Front Mol Biosci       Date:  2022-04-01

5.  Single-Cell RNA Sequencing Unravels Distinct Tumor Microenvironment of Different Components of Lung Adenocarcinoma Featured as Mixed Ground-Glass Opacity.

Authors:  Yu He; Fenglei Yu; Yi Tian; Qikang Hu; Bin Wang; Li Wang; Yan Hu; Yongguang Tao; Xiaofeng Chen; Muyun Peng
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

6.  m6A regulator-mediated RNA methylation modification patterns and immune microenvironment infiltration characterization in patients with intracranial aneurysms.

Authors:  Aierpati Maimaiti; Mirzat Turhon; Xiaojiang Cheng; Riqing Su; Kaheerman Kadeer; Aximujiang Axier; Dilimulati Ailaiti; Yirizhati Aili; Rena Abudusalamu; Ajimu Kuerban; Zengliang Wang; Maimaitili Aisha
Journal:  Front Neurol       Date:  2022-08-05       Impact factor: 4.086

7.  High expression of nectin-1 indicates a poor prognosis and promotes metastasis in hepatocellular carcinoma.

Authors:  Xuequan Wang; Ziming Xing; Huazhong Chen; Haihua Yang; Qiupeng Wang; Tongjing Xing
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.